Analysts at Aegis began coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research note issued on Monday. The brokerage set a “buy” rating and a $21.00 price target on the specialty pharmaceutical company’s stock. Aegis’ price target suggests a potential upside of 171.32% from the company’s current price.

REPH has been the subject of several other research reports. Brean Capital started coverage on shares of Recro Pharma in a research report on Monday, October 3rd. They set a “buy” rating and a $21.00 price target for the company. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research report on Wednesday, October 19th. Roth Capital started coverage on shares of Recro Pharma in a research report on Friday, September 16th. They set a “buy” rating and a $24.00 price target for the company. Janney Montgomery Scott started coverage on shares of Recro Pharma in a research report on Monday, August 29th. They set a “buy” rating and a $21.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating on shares of Recro Pharma in a research report on Monday, July 18th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $18.29.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) opened at 7.85 on Monday. The firm’s market capitalization is $77.47 million. The stock’s 50 day moving average is $7.80 and its 200-day moving average is $8.22. Recro Pharma has a one year low of $5.59 and a one year high of $12.50.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Fund Advisors raised its position in shares of Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 4,163 shares during the period. Northern Trust Corp acquired a new position in shares of Recro Pharma during the third quarter valued at about $128,000. Acadian Asset Management LLC acquired a new position in shares of Recro Pharma during the third quarter valued at about $140,000. Wells Fargo & Company MN raised its position in shares of Recro Pharma by 56.0% in the third quarter. Wells Fargo & Company MN now owns 31,200 shares of the specialty pharmaceutical company’s stock valued at $276,000 after buying an additional 11,200 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares during the last quarter. Institutional investors and hedge funds own 36.63% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.